Equillium announces Ono option lapse; pauses EQUATOR enrollment to review acceleration; cash runway into Q4 2025

Equillium, Inc.

Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.
EQUATOR Phase 3 study enrollment paused; company plans to accelerate topline data to Q1 2025 with ~150 patients.
Over 150 patients enrolled to date; orphan drug and fast track designations for first-line acute GVHD remain.
Biocon SA completed Phase 2 study of itolizumab in ulcerative colitis; topline data expected Q1 2025.
Company pauses EQ101 and EQ302 activities; cash runway expected into Q4 2025 with accelerated EQUATOR.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.